To establish the regulatory structure supporting the Compassionate Medical Cannabis Act of 2014

 

DEPARTMENT OF HEALTH

RULE NOS.:RULE TITLES:

64-4.001Definitions

64-4.002Initial Application Requirements for Dispensing Organizations

64-4.003Biennial Renewal Requirements for Dispensing Organizations

64-4.004Denial or Revocation for Dispensing Organization Approval

64-4.005Inspection Procedures

64-4.009Compassionate Use Registry

PURPOSE AND EFFECT: To establish the regulatory structure supporting the Compassionate Medical Cannabis Act of 2014.

SUMMARY: The rulemaking establishes a regulatory structure, including creation of dispensing regions; creation of applications, approval procedures, authorization procedures, and renewal procedures for dispensing organizations, and creation of access procedures for the Compassionate Use Registry.

SUMMARY OF STATEMENT OF ESTIMATED REGULATORY COSTS AND LEGISLATIVE RATIFICATION: The agency has determined that this will have an adverse impact on small business or likely increase directly or indirectly regulatory costs in excess of $200,000 in the aggregate within one year after the implementation of the rule. A SERC has not been prepared by the agency.

The Agency has determined that the proposed rule is not expected to require legislative ratification based on the statement of estimated regulatory costs or if no SERC is required, the information expressly relied upon and described herein: The rule requirements and cost estimates collected during rule development.

Any person who wishes to provide information regarding the statement of estimated regulatory costs, or to provide a proposal for a lower cost regulatory alternative must do so in writing within 21 days of this notice.

RULEMAKING AUTHORITY: 381.986 FS.

LAW IMPLEMENTED: 381.986 FS.

IF REQUESTED WITHIN 21 DAYS OF THE DATE OF THIS NOTICE, A HEARING WILL BE HELD AT THE DATE, TIME AND PLACE SHOWN BELOW:

DATE AND TIME: March 2, 2015, 8:00 a.m. ‒ 5:00 p.m., Eastern Time or until the hearing is concluded

PLACE: Department of Health, Room 301, 4052 Bald Cypress Way, Tallahassee, Florida 32399

Any person wanting to request a hearing regarding the proposed rule must do so within 21 days of the date of publication of this notice by contacting the agency’s designated contact, as described herein.

THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE IS: Patricia Nelson, Director of Office of Compassionate Use, 4052 Bald Cypress Way, Bin A-02, Tallahassee, Florida 32399-1703, E-mail: [e-mail]

 

THE FULL TEXT OF THE PROPOSED RULE IS:

 

64-4.001 Definitions.

For the purposes of this chapter, the following words and phrases shall have the meanings indicated:

(1) Applicant – A nursery that meets the requirements of Section 381.986(5)(b)1., F.S., applies for approval as a dispensing organization, and identifies a nurseryman as defined in Section 581.011, F.S., who will serve as the operator.

(2) Approval – Written notification from the department to an applicant that its application for dispensing organization approval has been found to be in compliance with the provisions of this chapter and that the department is awaiting notification that it is prepared to be inspected and authorized to begin cultivation, processing, and dispensing.

(3) Cultivation Authorization – Written notification by the department to a Dispensing Organization that it may begin cultivating low-THC cannabis.

(4) Processing Authorization – Written notification by the department to a Dispensing Organization that it may begin processing low-THC cannabis to Derivative Product.

(5) Dispensing Authorization – Written notification by the department to a Dispensing Organization that it may begin dispensing Derivative Product.

(6) Certified Financials – Financial statements that have been audited in accordance with Generally Accepted Auditing Standards (GAAS) by a Certified Public Accountant, licensed pursuant to Chapter 473, F.S.

(7) Cultivation – Growth of low-THC plant source material.

(8) Derivative Product – Forms of low-THC cannabis suitable for routes of administration.

(9) Dispensing Region – A geographical area where the cultivation and production of low-THC cannabis under the control of a Dispensing Organization occurs. The five dispensing regions shall be identified as follows:

(a) Northwest Florida Region consisting of Bay, Calhoun, Escambia, Franklin, Gadsden, Gulf, Holmes, Jackson, Jefferson, Leon, Liberty, Madison, Santa Rosa, Okaloosa, Taylor, Wakulla, Walton, and Washington counties.

(b) Northeast Florida Region consisting of Alachua, Baker, Bradford, Clay, Columbia, Dixie, Duval, Flagler, Gilchrist, Hamilton, Lafayette, Levy, Marion, Nassau, Putnam, St. Johns, Suwannee, and Union counties.

(c) Central Florida Region consisting of Brevard, Citrus, Hardee, Hernando, Indian River, Lake, Orange, Osceola, Pasco, Pinellas, Polk, Seminole, St. Lucie, Sumter, and Volusia counties.

(d) Southwest Florida Region consisting of Charlotte, Collier, DeSoto, Glades, Hendry, Highlands, Hillsborough, Lee, Manatee, Okeechobee, and Sarasota counties.

(e) Southeast Florida Region consisting of Broward, Miami-Dade, Martin, Monroe, and Palm Beach counties.

(10) Dispensing Organization – A nursery that meets the requirements of Section 381.986(5)(b)1., F.S., including its contractual agents, which has been authorized by the department to cultivate, process and dispense low-THC cannabis.

(11) Dispensing Organization Facility – Any of the following facilities:

(a) Cultivation Facility: Any area designated in the application to be used for cultivation of low-THC cannabis.

(b) Processing Facility: Any area designated in the application to be used for processing of Derivative Product.

(c) Dispensing Facility: Any area designated in the application where Derivative Product is dispensed at retail.

(12) Financial Statements – A presentation of financial data, including accompanying notes, derived from accounting records that purports to show actual or anticipated financial position and intended to communicate an entity's economic resources or obligations at a point in time, and the results of operations and cash flows for a period of time, in accordance with generally accepted accounting principles or a comprehensive basis of accounting other than generally accepted accounting principles. Financial presentations included in tax returns are not financial statements. The method of preparation (for example, manual or computer preparation) is not relevant to the definition of a financial statement.

(13) Manager – Any person with the authority to exercise operational direction or management of the Dispensing Organization or the authority to supervise any employee of the Dispensing Organization.

(14) Permanent resident – A person who has his or her true, fixed and permanent home, in Florida to which, whenever absent, he or she has the intention of returning. Once a permanent residence is established in Florida it is presumed to continue until the resident shows that a change has occurred. Any person who has established a residence in this state may manifest and evidence the same by filing a sworn statement pursuant to Section 222.17, F.S.

(15) Routes of administration – means the path by which a Derivative Product is ordered by a physician to be taken into the body of the qualified patient, but does not include smoking.

(16) Visitation Protocol - A set of identified policies and procedures of an applicant or Dispensing Organization that details requirements for visitor access to any proposed or existing Dispensing Organization facility.

Rulemaking Authority 381.986(5)(d) FS. Law Implemented 381.986(5)(b) FS. History–New_________.

 

64-4.002 Initial Application Requirements for Dispensing Organizations.

Each nursery that meets the requirements of Section 381.986(5)(b)1., F.S., desiring to be approved as a Dispensing Organization shall make application, either electronically or in hard copy, to the department using Form DH8006-OCU-2/2015, “Application for Low-THC Cannabis Dispensing Organization Approval” herein incorporated by reference and available at https://flrules.com/gateway/reference.asp?No=Ref-#####. The completed application form must include the following:

(1) An initial application fee of $60,063.00.

(2) An explanation or written documentation, as applicable, showing how the Applicant meets the statutory criteria listed in Section 381.986(5)(b), F.S. In any explanation, the Applicant must address each item listed for each criterion below. The Applicant must disclose the name, position, and resume of the employee(s) who provides the knowledge or experience explained for each item.

(a) The technical and technological ability to cultivate, process, and dispense low-THC cannabis. Please address the following items:

1. Experience cultivating cannabis;

2. Experience cultivating in Florida plants not native to Florida;

3. Experience introducing new varieties of plants;

4. Regional cultivation knowledge and experience;

5. Experience cultivating plants for human consumption such as food or medicine products;

6. Experience with in-house propagation;

7. Experience with genetic modification or breeding;

8. Experience using clean growing rooms;

9. Knowledge of cannabis cultivation, including:

a. Proper cultivation conditions and techniques;

b. Additives that can be used when growing cannabis;

c. Pests, disease and deficiencies common for cannabis;

d. Production of high quality product in a short time;

10. Experience with tracking each plant in a harvest;

11. Experience with good agricultural practices;

13. Experience with good handling practices;

14. Experience with good manufacturing practices;

15. Experience with analytical, organic chemistry, and micro-biology;

16. Experience with analytical laboratory methods;

17. Experience with analytical laboratory quality control, including maintaining a chain of custody;

18. Knowledge of and experience with cannabis extraction techniques;

19. Knowledge of cannabis routes of administration;

20. Knowledge of and experience with producing cannabis products;

21. Experience interacting with patients;

22. Experience with handling confidential information;

23. A marketing plan;

24. Experience gathering and managing data, i.e. data on patient reactions to products dispensed;

25. Experience with recalls;

26. Training programs for employees addressing:

a. The Health Insurance Portability and Accountability Act (HIPAA);

b. Patient education;

c. Compliance;

d. Patient counseling; and

e. Data collection.

27. Any awards, recognition or certifications received for relevant expertise.

(b) Written documentation demonstrating that the applicant must possesses a valid certificate of registration issued by the Department of Agriculture and Consumer Services pursuant to Section 581.131 that is issued for the cultivation of more than 400,000 plants, is operated by a nurseryman as defined in Section 581.011, and has been operated as a registered nursery in this state for at least 30 continuous years.

(c) The ability to secure the premises, resources, and personnel necessary to operate as a Dispensing Organization. Please address the following items, and include a sketch or other illustration:

1. Location of all properties Applicant proposes to utilize to cultivate, process, and dispense low-THC cannabis and Derivative Product, including ownership information for the properties and any lease terms if applicable;

a. For any property that is leased by the Applicant, include documentation that the property owner consents to the use of the property for the purposes of cultivation, processing, or dispensing of low-THC cannabis and Derivative Products and documentation that the mortgagor or lienholder has been given notice of the use of the property for the purposes of cultivation, processing, or dispensing of low-THC cannabis and Derivative Products.

b. For any property owned by the Applicant but subject to a mortgage or lien, include documentation that the mortgagor or lienholder has been notified of the use of the property for the purposes of cultivation, processing, or dispensing of low-THC cannabis and Derivative Products.

2. Compliance with local regulations regarding sanitation and waste disposal;

3. The ability to obtain zoning approval;

4. Sketch or other illustration approximating the property boundaries, land topography, vegetation, proposed and/or existing structures, easements, wells, and roadways for each property proposed;

5. Description of the areas proposed for the cultivation of low-THC cannabis, including the following:

a. Capacity, in square feet of growing area;

b. Cultivation environment, e.g., greenhouse, clean room, aseptic, et cetera;

c. Irrigation system(s); and

d. Environmental control system(s);

6. A description of the ability or plan to expand any of the areas proposed for low-THC cannabis;

7. Back-up systems for all cultivation and processing systems;

8. A description of one or more strains of low-THC cannabis the applicant intends to cultivate;

9. Access to water resources that allow for sufficient irrigation;

10. Description of the areas proposed for the processing of Derivative Products, including the following:

a. Extraction equipment and location;

b. Concentration equipment and location;

c. Access to sufficient potable water and hot water;

d. Analytical equipment, including separators and detectors, and location;

e. Safety equipment and facilities and location;

f. Computer systems and software; and

g. Ventilation and exhaust system.

11. Description of the methods proposed for the dispensing of Derivative Products, including the following:

a. Accessibility of dispensing facilities, e.g., centrally located to several populated areas, located on a main roadway, not in a high crime area, et cetera;

b. Proximity of dispensing facilities to patient populations; and

c. Alternative dispensing, e.g. delivery.

12. A list of current and proposed staffing, including;

a. Position, duties and responsibilities;

b. Resume; and

c. Professional licensure disciplinary action in all jurisdictions.

13. An organizational chart illustrating the supervisory structure of the proposed Dispensing Organization;

14. Plans and procedures for loss of key personnel;

15. Plans and procedures for complying with OSHA regulations for workplace safety; and

16. Relationship(s) with an independent laboratory(ies) with cannabis testing protocols and methods.

(d) The ability to maintain accountability of all raw materials, finished products, and any byproducts to prevent diversion or unlawful access to or possession of these substances. Please address the following items for each property or location:

1. Floor plan of each facility or proposed floor plans for proposed facilities, including the following:

a. Locking options for each means of ingress and egress;

b. Alarm systems;

c. Video surveillance;

d. Name and function of each room;

e. Layout and dimensions of each room;

2. Storage, including the following;

a. Safes;

b. Vaults;

c. Climate control;

3. Diversion and trafficking prevention procedures;

4. A facility emergency management plan;

5. System for tracking low-THC source plant material throughout cultivation, processing, and dispensing;

6. Inventory control system for low-THC cannabis and Derivative Products;

7. Policies and procedures for recordkeeping;

8. Vehicle tracking systems;

9. Vehicle security systems;

10. Methods of screening and monitoring employees;

11. Personnel qualifications and experience with chain of custody or other tracking mechanisms;

12. Personnel reserved solely for inventory control purposes;

13. Personnel reserved solely for security purposes;

14. Waste disposal plan;

15. Plans for the recall of any Derivative Products that have a reasonable probability of causing adverse health consequences based on a testing result, bad patient reaction, or other reason; and

16. Access to specialized resources or expertise regarding data collection, security, and tracking.

(e) An infrastructure reasonably located to dispense low-THC cannabis to registered patients statewide or regionally as determined by the department. Please address the following items:

1. A map showing the location of the applicant’s proposed dispensing facilities;

2. A sketch or other illustration of the actual or proposed dispensing location showing streets; property lines; buildings; parking areas; outdoor areas, if applicable; fences; security features; fire hydrants, if applicable; and access to water and sanitation systems; and

3. A floor plan of the actual or proposed building or buildings where dispensing activities will occur showing:

a. Areas designed to protect patient privacy;

b. Areas designed for retail sales;

4. A HIPAA compliant computer network utilized by all facilities;

5. Vehicles that will be used to transport product among cultivating, processing, and dispensing facilities;

6. Communication systems;

7. Hours of operation of each dispensing facility; and

8. Methods of mitigating odors if applicable.

(f) The financial ability to maintain operations for the duration of the 2-year approval cycle, including the provision of Certified Financials to the department. Please provide the following items:

1. Certified Financials issued within the immediately preceding 12 months;

2. Applicant’s corporate structure;

3. All owners of the Applicant;

4. All individuals and entities that can exercise control of the Applicant;

5. All individuals and entities that share in the profits and losses of the Applicant;

6. All subsidiaries of the Applicant;

7. Any other individuals or entities for which the Applicant is financially responsible;

8. Assets of the Applicant and Applicant’s subsidiaries;

9. Liabilities of the Applicant and Applicant’s subsidiaries;

10. Any pending lawsuits to which the Applicant is a party;

11. Any lawsuits within the past 7 years to which the Applicant was a party;

12. All financial obligations of Applicant that are not listed as a “liability” in the Certified Financials;

13. A projected two year budget; and

14. Specific reference to sufficient assets available to support the Dispensing Organization activities.

(g) That all owners and managers have been fingerprinted and have successfully passed a level 2 background screening pursuant to Section 435.04, F.S., within the calendar year prior to application. Each owner and manager should present to FDLE or one of its approved vendors for fingerprinting. At that time, give the entity ORI number FL924890Z (DOH – OFFICE OF COMPASSIONATE USE). The report will be sent directly to the Office of Compassionate Use. Please submit a list of all owners and managers indicating the date of each individual’s most recent Level-2 background screening.

(h) The employment of a medical director who is a physician licensed pursuant to Chapter 458 or Chapter 459, F.S., to supervise the activities of the proposed Dispensing Organization. Please address the following items for the physician chosen as medical director:

1. Specialty area, if any;

2. Experience with epileptic patients;

3. Experience with cancer patients;

4. Experience with patients with severe seizures or muscle spasms;

5. Knowledge of the use of low-THC cannabis for treatment of cancer or physical medical conditions that chronically produce symptoms of seizures or severe and persistent muscle spasms;

6. Knowledge of good manufacturing practices;

7. Knowledge of analytical and organic chemistry;

8. Knowledge of analytical laboratory methods;

9. Knowledge of analytical laboratory quality control, including maintaining a chain of custody;

10. Knowledge of and experience with CBD/low-THC extraction techniques;

11. Knowledge of CBD/low-THC routes of administration;

12. Experience in or knowledge of clinical trials or observational studies;

13. Knowledge of and experience with producing CBD/low-THC products;

14. Experience with or knowledge of botanical medicines;

15. Experience with dispensing medications;

16. Description of how the medical director will supervise the activities of the Dispensing Organization; and

17. Description of how the Dispensing Organization will ensure it has a medical director at all times.

(i) The ability to post a $5 million performance bond for the biennial approval cycle.

(3) If the Applicant intends to claim any exemption from public records disclosure under Section 119.07, F.S., or any other exemption from public records disclosure provided by law for any part of its application, it shall indicate on the application the specific sections for which it claims an exemption and the statutory basis for the exemption. The Applicant shall submit a redacted copy of the application redacting those items identified as exempt.

(4) Failure to submit the $60,063.00 application fee or documentation sufficient to establish the Applicant meets the requirements of Section 381.986(5)(b), F.S., shall result in the application being denied prior to any scoring as contemplated in Section (5) of this rule.

(5) Any “Application for Low-THC Cannabis Dispensing Organization Approval” and all required exhibits and supporting documents shall be delivered to the Agency Clerk of the Department of Health physically located at 2585 Merchants Row Boulevard in Tallahassee, Florida, no earlier than 10:00 AM, Eastern Time, on the effective date of this rule and no later than 5:00 PM, Eastern Time, 21 calendar days after the effective date of this rule.

(a) The department will substantively review, evaluate, and score applications using Form DH8007-OCU-2/2015, “Scorecard for Low-THC Cannabis Dispensing Organization Selection” herein incorporated by reference and available at https://flrules.com/gateway/reference.asp?No=Ref-#####. The department’s substantive review will be completed by:

1. Director of the Office of Compassionate Use;

2. A member of the Drug Policy Advisory Council appointed by the State Surgeon General; and

3. A Certified Public Accountant appointed by the State Surgeon General.

(b) Each reviewer will independently review each application and score using Form DH8007-OCU-2/2015, “Scorecard for Low-THC Cannabis Dispensing Organization Selection.” Scorecards from each reviewer will be combined to generate an aggregate score for each application. The Applicant with the highest aggregate score in each dispensing region shall be selected as the region’s Dispensing Organization.

(c) In the event of a tie in a region, each reviewer will re-review the tied applications and select a winning application. The department will approve the application selected by the majority of the reviewers.

(d) In the event one nursery receives the high score in multiple regions, one of which is the region represented by the address on the nursery’s certificate of registration, the Applicant will be approved for that region, and the second highest scored Applicant will be approved for the other region(s). In the event one nursery receives the high score in multiple regions, none of which is the region represented by the address on the nursery’s certificate of registration, the Applicant will be approved for the region for which it had the highest aggregate infrastructure score, and the second highest scored Applicant will be approved for the other region(s).

(e) Upon notification that it has been approved as a region’s Dispensing Organization, the Applicant shall have 10 business days to post a $5 million performance bond. The bond shall:

1. Be payable to the department in the event the Dispensing Organization’s approval is revoked;

2. Be written by a surety company licensed by the Florida Office of Insurance Regulation.

3. Be written so that the nursery name on the bond corresponds exactly with the Applicant name.

4. If a bond is canceled and the Dispensing Organization fails to file a new bond with the department in the required amount on or before the effective date of cancellation, the Dispensing Organization’s approval shall be revoked.

(f) If the selected Applicant fails to post the bond within the required timeframe, the Applicant with the next highest score in the dispensing region shall be selected and notified.

(g) The surety company can use any form it prefers for the performance bond as long as it complies with this rule. For convenience, the surety company can also use Form DH8008-OCU-2/2015, “Florida Low-THC Cannabis Performance Bond” herein incorporated by reference and available at https://flrules.com/gateway/reference.asp?No=Ref-#####.

Rulemaking Authority 381.986(5)(d) FS. Law Implemented 381.986(5)(b) FS. History–New_________.

 

64-4.003 Biennial Renewal Requirements for Dispensing Organizations.

(1) No less than six months prior to the expiration of an existing Dispensing Organization’s two year approval to dispense Derivative Products, the Dispensing Organization shall make application for renewal of the Dispensing Organization approval using Form DH8006-OCU-2/2015, “Application for Low-THC Cannabis Dispensing Organization Approval” herein incorporated by reference and available at https://flrules.com/gateway/reference.asp?No=Ref-#####, indicating that the application is a renewal application.

(2) In addition to the completed application form, Dispensing Organization renewal applicants shall:

(a) Provide proof that a $5 million performance bond remains in effect.

(b) Report how much Derivative Product was processed, dispensed, and destroyed in the previous two years of operation; and

(c) Report how many patients were served in the previous two years of operation.

(3) If the Dispensing Organization meets the requirements of Section 381.986(5)(b), F.S., and this chapter, the department shall notify the Dispensing Organization that it intends to renew the approval.

(4) Upon notification that its renewal will be approved, the Dispensing Organization shall have 30 calendar days to pay a nonrefundable renewal fee equal to the biennial costs of administering Section 381.986 F.S., divided by the number of renewal applicants.

(5) If the Dispensing Organization fails to renew within the required timeframes, the department shall seek new applications for a Dispensing Organization in the applicable dispensing region by posting notice in the Florida Administrative Register and thereafter following the procedures in Rule 64-4.002, F.A.C.

(6) A Dispensing Organization that fails to renew its approval shall not dispense Derivative Products after midnight local time on the date that its authorization expires and shall destroy through incineration all low-THC cannabis and Derivative Product in its possession within 48 hours of the last dispensing day.

Rulemaking Authority 381.986(5)(d) FS. Law Implemented 381.986(5)(a); 837.06 FS. History–New_________.

 

64-4.004 Revocation of Dispensing Organization Approval.

(1) The department shall revoke its approval of the Dispensing Organization if the Dispensing Organization does any of the following:

(a) Cultivates low-THC cannabis before obtaining department authorization;

(b) Knowingly dispenses Derivative Product to an individual other than a qualified patient or a qualified patient’s legal representative without noticing the department and taking appropriate corrective action;

(2) The department may revoke its approval of the Dispensing Organization if any of the following failures impact the accessibility, availability, or safety of the Derivative Product and are not corrected within 30 calendar days after notification to the Dispensing Organization of the failure;

(a) Failure to comply with the requirements in Section 381.986, F.S., or this rule chapter;

(b) Failure to implement the policies and procedures or comply with the statements provided to the department with the original or renewal application;

(3) The department may revoke its approval of the Dispensing Organization for failure to meet the following deadlines if failure is not corrected within 10 calendar days:

(a) Failure to seek Cultivation Authorization within 75 calendar days of application approval; or

(b) Failure to begin dispensing within 210 calendar days of the being granted the Cultivation Authorization requested in subsection 64-4.005(2), F.A.C.

Rulemaking Authority 381.986(5)(d) FS. Law Implemented 381.986(5)(b) FS. History–New_________.

 

64-4.005 Inspection and Authorization Procedures.

(1) Submission of an application for Dispensing Organization approval or renewal constitutes permission for entry by the department at any reasonable time during the approval or renewal process, into any Dispensing Organization facility to inspect any portion of the facility; review the records required pursuant to Section 381.986, F.S., or this chapter; and identify samples of any low-THC cannabis or Derivative Product for laboratory analysis, the results of which shall be forwarded to the department. All inspectors shall follow the Dispensing Organization’s Visitation Protocol when conducting any inspection.

(2) A Dispensing Organization must request Cultivation Authorization within 75 days of being notified that it has been approved as a region’s Dispensing Organization. No less than 30 calendar days prior to the initial cultivation of low-THC cannabis, the Dispensing Organization shall notify the department that the Dispensing Organization is ready to begin cultivation, the Dispensing Organization is in compliance with Section 381.986, F.S., and this rule chapter and is seeking Cultivation Authorization. No low-THC cannabis plant source material, may be present in any Dispensing Organization facility prior to Cultivation Authorization.

(3) No less than 10 calendar days prior to the initial processing of low-THC cannabis, the Dispensing Organization shall notify the department that the Dispensing Organization is ready to begin processing, the Dispensing Organization is in compliance with Section 381.986, F.S., and this chapter, and is seeking Processing Authorization.

(4) A Dispensing Organization must begin dispensing Derivative Product within 210 days of being granted Cultivation Authorization. No less than 10 calendar days prior to the initial dispensing of Derivative Product, the Dispensing Organization shall notify the department that the Dispensing Organization is ready to begin dispensing, the Dispensing Organization is in compliance with Section 381.986, F.S., and this chapter, and is seeking Dispensing Authorization.

(5) If the department identifies a violation of Section 381.986, F.S., or this chapter during an inspection of a Dispensing Organization facility, the Dispensing Organization shall notify the department in writing, within 20 calendar days after the date of receipt of the written notice of violation, identifying the corrective action taken and the date of the correction.

Rulemaking Authority 381.986(5)(d) FS. Law Implemented 381.986(5)(b) FS. History–New_________.

 

64-4.009 Compassionate Use Registry.

(1) Ordering physicians licensed under Chapter 458 or 459, F.S., meeting the educational requirements of Section 381.986(4), F.S., may access the Compassionate Use Registry using their existing MQA Services credentials.

(2) Other persons may request access to the Compassionate Use Registry by completing form DH8009-OCU-2/2015, “Request for Access to the Compassionate Use Registry,” herein incorporated by reference and available at https://flrules.com/gateway/reference.asp?No=Ref-#####. Those requesting access must meet one of the following criteria:

(a) Authorized employee of a Dispensing Organization;

(b) Law enforcement official; or

(c) Authorized employee of the department.

(3) Persons seeking to access to the registry shall have successfully completed a department-approved course in their responsibilities related to patient confidentiality and shall make documentation of completion available to the department upon request.

(4) Before dispensing any Derivative Product to a qualified registered patient or the patient’s legal representative, the Dispensing Organization must verify that the patient has an active registration, the order presented matches the order contents as recorded by the physician in the registry, and the order has not already been dispensed.

(5) The Dispensing Organization shall enter a dispensing action into the registry immediately upon dispensing the Derivative Product to the qualified registered patient or the patient’s legal representative.

Rulemaking Authority 381.986(5)(d) FS. Law Implemented 381.986(5)(a); 837.06 FS. History–New_________.

 

NAME OF PERSON ORIGINATING PROPOSED RULE: Patricia Nelson

NAME OF AGENCY HEAD WHO APPROVED THE PROPOSED RULE: John H. Armstrong, MD, FACS, Surgeon General and Secretary

DATE PROPOSED RULE APPROVED BY AGENCY HEAD: February 5, 2015

DATE NOTICE OF PROPOSED RULE DEVELOPMENT PUBLISHED IN FAR: January 5, 2015